Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2
© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics..
Tocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). We evaluated patients treated with tocilizumab for a SARS-CoV-2 infection who were admitted between March 13, 2020, and April 16, 2020. This was a multicenter study with data collected by chart review both retrospectively and concurrently. Parameters evaluated included age, sex, race, use of mechanical ventilation (MV), usage of steroids and vasopressors, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within 1 day of intubation. Late dosing was defined as a dose administered > 1 day after intubation. In the absence of MV, the timing of the dose was related to the patient's date of admission only. We evaluated 145 patients. The average age was 58.1 years, 64% were men, 68.3% had comorbidities, and 60% received steroid therapy. Disposition of patients was 48.3% discharged and 29.3% died, of which 43.9% were African American. MV was required in 55.9%, of which 34.5% died. Avoidance of MV (P = 0.002) and increased survival (P < 0.001) was statistically associated with early dosing. Tocilizumab therapy was effective at decreasing mortality and should be instituted early in the management of critically ill patients with coronavirus disease 2019) COVID-19).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Clinical and translational science - 14(2021), 6 vom: 14. Nov., Seite 2146-2151 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Petrak, Russell M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 30.11.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cts.12894 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314909265 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314909265 | ||
| 003 | DE-627 | ||
| 005 | 20231225153746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cts.12894 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM314909265 | ||
| 035 | |a (NLM)32918792 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Petrak, Russell M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. | ||
| 520 | |a Tocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). We evaluated patients treated with tocilizumab for a SARS-CoV-2 infection who were admitted between March 13, 2020, and April 16, 2020. This was a multicenter study with data collected by chart review both retrospectively and concurrently. Parameters evaluated included age, sex, race, use of mechanical ventilation (MV), usage of steroids and vasopressors, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within 1 day of intubation. Late dosing was defined as a dose administered > 1 day after intubation. In the absence of MV, the timing of the dose was related to the patient's date of admission only. We evaluated 145 patients. The average age was 58.1 years, 64% were men, 68.3% had comorbidities, and 60% received steroid therapy. Disposition of patients was 48.3% discharged and 29.3% died, of which 43.9% were African American. MV was required in 55.9%, of which 34.5% died. Avoidance of MV (P = 0.002) and increased survival (P < 0.001) was statistically associated with early dosing. Tocilizumab therapy was effective at decreasing mortality and should be instituted early in the management of critically ill patients with coronavirus disease 2019) COVID-19) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Skorodin, Nathan C |e verfasserin |4 aut | |
| 700 | 1 | |a Van Hise, Nicholas W |e verfasserin |4 aut | |
| 700 | 1 | |a Fliegelman, Robert M |e verfasserin |4 aut | |
| 700 | 1 | |a Pinsky, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Didwania, Vishal |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz, Melina |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Kairav |e verfasserin |4 aut | |
| 700 | 1 | |a Chundi, Vishnu V |e verfasserin |4 aut | |
| 700 | 1 | |a Hines, David W |e verfasserin |4 aut | |
| 700 | 1 | |a Harting, Brian P |e verfasserin |4 aut | |
| 700 | 1 | |a Sidwha, Kamo |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Brune, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Owaisi, Anjum |e verfasserin |4 aut | |
| 700 | 1 | |a Beezhold, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kent, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Vais, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Gowda, Neethi |e verfasserin |4 aut | |
| 700 | 1 | |a Sahgal, Nishi |e verfasserin |4 aut | |
| 700 | 1 | |a Silverman, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Stake, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Nepomuceno, Jenie |e verfasserin |4 aut | |
| 700 | 1 | |a Heddurshetti, Renuka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational science |d 2008 |g 14(2021), 6 vom: 14. Nov., Seite 2146-2151 |w (DE-627)NLM186388268 |x 1752-8062 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:6 |g day:14 |g month:11 |g pages:2146-2151 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cts.12894 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 6 |b 14 |c 11 |h 2146-2151 | ||